These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 18323826)
21. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience. Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080 [TBL] [Abstract][Full Text] [Related]
22. [Lenalidomide. Treatment of multiple myeloma]. Musch A Med Monatsschr Pharm; 2008 Jan; 31(1):4-8; quiz 9-10. PubMed ID: 18522014 [No Abstract] [Full Text] [Related]
24. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma. Dasanu CA; Alexandrescu DT Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868 [TBL] [Abstract][Full Text] [Related]
25. Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma. Modi D; Mamdani H; Vettese T Am J Med Sci; 2015 Sep; 350(3):241-2. PubMed ID: 26200951 [No Abstract] [Full Text] [Related]
26. Thalidomide-induced severe hepatotoxicity. Dabak V; Kuriakose P Cancer Chemother Pharmacol; 2009 Mar; 63(4):583-5. PubMed ID: 19083237 [No Abstract] [Full Text] [Related]
27. Interstitial granulomatous drug reaction due to thalidomide. Yazganoğlu KD; Tambay E; Mete O; Ozkaya E J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):490-3. PubMed ID: 19335735 [No Abstract] [Full Text] [Related]
28. Thalidomide and immunomodulatory drugs in the treatment of cancer. Bamias A; Dimopoulos MA Expert Opin Investig Drugs; 2005 Jan; 14(1):45-55. PubMed ID: 15709921 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of thalidomide in the treatment of multiple myeloma. Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865 [No Abstract] [Full Text] [Related]
30. Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. Gieseler F Thromb Haemost; 2008 Jun; 99(6):1001-7. PubMed ID: 18521500 [TBL] [Abstract][Full Text] [Related]
31. Hepatotoxicity as a rare but serious side effect of thalidomide. Levesque E; Bradette M Ann Hematol; 2009 Feb; 88(2):183-4. PubMed ID: 18665361 [No Abstract] [Full Text] [Related]
32. Toward an effective targeted chemotherapy for multiple myeloma. Polson AG; Sliwkowski MX Clin Cancer Res; 2009 Jun; 15(12):3906-7. PubMed ID: 19509145 [TBL] [Abstract][Full Text] [Related]
33. The drugs from within. Bolander F Curr Opin Investig Drugs; 2009 Apr; 10(4):303-4. PubMed ID: 19337949 [No Abstract] [Full Text] [Related]
34. Lenalidomide in the treatment of multiple myeloma: a review. Armoiry X; Aulagner G; Facon T J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408 [TBL] [Abstract][Full Text] [Related]
35. Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide. Srinivasan S; Schiffer CA Leuk Res; 2009 Apr; 33(4):561-4. PubMed ID: 18676017 [TBL] [Abstract][Full Text] [Related]
36. Multiple myeloma: challenges and opportunities. Joshua D; Brown R; Ho PJ Methods Mol Med; 2005; 113():1-4. PubMed ID: 15968090 [No Abstract] [Full Text] [Related]
37. New drugs in multiple myeloma. Berenson JR; Yellin O Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422 [TBL] [Abstract][Full Text] [Related]
38. Neutrophilic dermatosis complicating lenalidomide therapy. Thieu KP; Rosenbach M; Xu X; Kist JM J Am Acad Dermatol; 2009 Oct; 61(4):709-10. PubMed ID: 19577327 [TBL] [Abstract][Full Text] [Related]